Coronary Intervention & Surgery

A low measure of base excess (BE) upon admission to the ICU following cardiac surgery was independently predictive of ICU mortality—more so than increased lactate levels, researchers reported in PLOS One.

The considerable survival advantage observed in female patients undergoing transcatheter aortic valve implantation (TAVI) during the procedure’s earlier years has diminished in the contemporary TAVI era, according to research out of Petah Tikva, Israel, meaning men and women are seeing similar outcomes post-procedure.

Fractional flow reserve (FFR) can be closely approximated using conventional coronary angiography and propriety software, according to the FAST-FFR study published online in Circulation. The findings offer a potential route for more patients with suspected coronary artery disease to receive functional assessment of lesions without the need for a guidewire or hyperemic agents.

In patients with atrial fibrillation who have experienced MI or undergone percutaneous coronary intervention (PCI), treatment with a combination of direct oral anticoagulants (DOACs) and dual antiplatelet therapy (DAPT) could significantly decrease the risk of bleeding and other major thromboembolic events, according to research published ahead of print in the Journal of the American College of Cardiology.

The prices of implantable medical devices to treat heart patients are up to six times higher in the United States than Germany, according to a study published Oct. 1 in Health Affairs.

Same-day discharge following elective percutaneous coronary intervention (PCI) was safe and resulted in more than $5,000 in savings per procedure, according to an analysis of operations performed from 2006 through 2015. Yet only 9.1 percent of interventions that were studied achieved same-day discharge, representing an opportunity to trim healthcare costs in the United States.

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.

Cardiologists at Henry Ford Hospital in Detroit have successfully performed the country’s first implantation of the Neovasc Reducer—a stainless steel, hourglass-shaped heart mesh designed to alleviate difficult angina—the hospital announced in a statement Sept. 26.

With additional testing for nonobstructive coronary artery disease (CAD), researchers effectively diagnosed microvascular and/or vasospastic angina—as well as non-cardiac related chest pain—and used that information to guide therapy decisions and significantly improve angina and quality-of-life outcomes.

Intravascular ultrasound (IVUS)-guided stent implantation offers improved clinical outcomes for heart patients over a traditional angiography-guided approach, researchers from China reported at this week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Diego, California.

A novel, polymer-free amphilius-eluting stent known as the “Cre8” was proven noninferior to the latest-generation permanent polymer drug-eluting stent in the first large-scale trial of its kind, according to research presented at the Cardiovascular Research Foundation’s 30th annual TCT conference in San Diego.